AN2728 is a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. AN2728 inhibits PDE4 and reduces the production of TNF-alpha, a precursor of the inflammation associated with psoriasis as well as other cytokines, including IL-12 and IL-23, which are proteins believed to be involved in the inflammation process and immune responses. AN2728 is currently in Phase 2b for psoriasis and Phase 2 for atopic dermatitis.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis.
Nazarian R, et al. Curr Opin Investig Drugs. 2009 Nov;10(11):1236-42. PMID: 19876791.
|Related PDE Products|
IBMX is a pDE inhibitor (non-selective).
GLPG1690 is a first-in-class autotaxin (ATX) inhibitor, with IC50 of 131 nM and Ki of 15 nM.
RVT-501 (E6005) is a selective phosphodiesterase 4 (PDE4PDE4) inhibitor with an IC50 of 2.8 nM.
Vardenafil Hcl is a PDE5 inhibitor used for treating erectile dysfunction.
Udenafil(DA8159) is a PDE5 inhibitor used in urology to treat erectile dysfunction.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.